BR0008416A - Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila - Google Patents

Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila

Info

Publication number
BR0008416A
BR0008416A BR0008416-6A BR0008416A BR0008416A BR 0008416 A BR0008416 A BR 0008416A BR 0008416 A BR0008416 A BR 0008416A BR 0008416 A BR0008416 A BR 0008416A
Authority
BR
Brazil
Prior art keywords
treatment
methods
potassium
resistance
cell
Prior art date
Application number
BR0008416-6A
Other languages
English (en)
Inventor
Grant Andrew Mc-Naughton-Smith
Gregory Gooksey Rigdon
Jonathan Walter Stocker
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of BR0008416A publication Critical patent/BR0008416A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, FORMULAçãO E COMPOSIçãO FARMACêUTICAS, MéTODOS PARA INIBIR O FLUXO DE POTáSSIO DE UMA CéLULA, PARA O TRATAMENTO OU PREVENçãO DE UM EVENTO DE DOENçA FALCIFORME, E, PARA MELHORAR A RESISTêNCIA à DEGRADAçãO EM UM MEIO BIOLóGICO DE UM INIBIDOR DE CANAL DE POTáSSIO COMPREENDENDO UMA PORçãO FENILA". Novos inibidores de fluxo de potássio são descritos. Os inibidores mostram surpreendente resistência à degradação em meios biológicos e melhoradas meia-vidas ín vivo com relação aos homólogos substituídos não flúor. Os métodos para uso destes compostos incluem o tratamento de doença falciforme, evitando a desidratação de eritrócitos e a inibição de fluxo de potássio.
BR0008416-6A 1999-02-23 2000-02-10 Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila BR0008416A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13551199P 1999-02-23 1999-02-23
US09/386,601 US6288122B1 (en) 1999-02-23 1999-08-31 Gardos channel antagonists
PCT/US2000/003663 WO2000050026A1 (en) 1999-02-23 2000-02-10 Gardos channel antagonists

Publications (1)

Publication Number Publication Date
BR0008416A true BR0008416A (pt) 2002-01-29

Family

ID=26833406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008416-6A BR0008416A (pt) 1999-02-23 2000-02-10 Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila

Country Status (16)

Country Link
US (1) US6288122B1 (pt)
EP (1) EP1158971B1 (pt)
JP (2) JP4038337B2 (pt)
KR (1) KR100705726B1 (pt)
CN (1) CN1193748C (pt)
AP (1) AP1465A (pt)
AT (1) ATE370728T1 (pt)
AU (1) AU762039B2 (pt)
BR (1) BR0008416A (pt)
CA (1) CA2371857C (pt)
DE (1) DE60036093T2 (pt)
ES (1) ES2291191T3 (pt)
HK (1) HK1045262B (pt)
IL (2) IL145012A0 (pt)
OA (1) OA11838A (pt)
WO (1) WO2000050026A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
EP1911740B1 (en) 2002-01-04 2013-02-27 NeuroSearch A/S Potassium channel modulators
JP2005526052A (ja) * 2002-02-28 2005-09-02 アイカゲン インコーポレイテッド 眼内圧に関連する疾患を処置するための方法
WO2005003143A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Novel potassium channel modulators
US20070027205A1 (en) * 2003-07-03 2007-02-01 Joachim Demnitz Diarylmethyl derivatives as potassium channel modulators
CA2594505A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
CN101437403A (zh) * 2005-12-20 2009-05-20 Icagen公司 使用三芳基甲烷化合物的治疗方法
ATE494891T1 (de) 2007-08-24 2011-01-15 Neurosearch As Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
ES2636563T3 (es) 2008-04-09 2017-10-06 Cerus Corporation Método de reducción de la deshidratación en una composición de glóbulos rojos
JP5783903B2 (ja) 2008-11-10 2015-09-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間コンダクタンスカルシウム活性化カリウムチャネルを介して細胞間融合を調節するための組成物および方法
WO2016134353A1 (en) * 2015-02-20 2016-08-25 Children's Medical Center Corporation Methods for treating malaria using potassium channel inhibitors
EP3106155A1 (en) * 2015-06-15 2016-12-21 Universite d'Aix Marseille Treatment and diagnosis of hereditary xerocytosis
EP3532045A4 (en) * 2016-10-25 2020-07-22 Paracelsus Neuroscience LLC USE OF SENICAPOC FOR THE TREATMENT OF NEUROPATHIC PAIN
WO2018162426A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment and diagnosis of hereditary xerocytosis
CN112020353A (zh) * 2019-03-29 2020-12-01 深圳仁泰医药科技有限公司 2,2-双(4-氟苯基)-2-苯乙酰胺的晶型a及其制备方法和应用
US20230045322A1 (en) * 2019-07-29 2023-02-09 Paracelsus Neuroscience II, LLC Use of senicapoc for treatment of stroke
WO2022015893A2 (en) * 2020-07-14 2022-01-20 Adimabio Llc Compositions comprising gardos channel antagonists and their uses
CA3201648A1 (en) 2020-12-11 2022-06-16 Robin VAN BRUGGEN Treatment and prevention of anaemia of inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
AU732881C (en) 1994-09-16 2002-11-07 Children's Medical Center Corporation Triaryl and diaryl compounds, their analogues and uses thereof

Also Published As

Publication number Publication date
CA2371857C (en) 2008-07-29
WO2000050026A1 (en) 2000-08-31
IL145012A (en) 2006-12-10
JP2007262075A (ja) 2007-10-11
AP2001002268A0 (en) 2001-09-30
DE60036093D1 (de) 2007-10-04
AU762039B2 (en) 2003-06-19
HK1045262A1 (en) 2002-11-22
AU2880700A (en) 2000-09-14
US6288122B1 (en) 2001-09-11
OA11838A (en) 2005-08-22
HK1045262B (zh) 2005-07-29
IL145012A0 (en) 2002-06-30
CN1193748C (zh) 2005-03-23
EP1158971A4 (en) 2003-04-16
EP1158971A1 (en) 2001-12-05
AP1465A (en) 2005-09-22
ATE370728T1 (de) 2007-09-15
EP1158971B1 (en) 2007-08-22
ES2291191T3 (es) 2008-03-01
JP2002537331A (ja) 2002-11-05
CN1344158A (zh) 2002-04-10
KR20020002393A (ko) 2002-01-09
DE60036093T2 (de) 2008-05-15
JP4038337B2 (ja) 2008-01-23
KR100705726B1 (ko) 2007-04-11
CA2371857A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
BR0008416A (pt) Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila
AP2000001934A0 (en) Antipicornaviral compounds, their preparation and use.
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BRPI0409417A (pt) método para usar um composto, composto, e, composição
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
TR200001203T2 (tr) Yeni birleşik maddeler
SE0001899D0 (sv) New compounds
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
BRPI0408784A (pt) método para usar um composto
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
BR0109703A (pt) Derivados de piperazina
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
PT1206484E (pt) Compostos e composicoes antipicornavirais, suas utilizacoes farmaceuticas e materiais para a sua sintese
BRPI0414215A (pt) tienopirazóis
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
SE0302546D0 (sv) New compounds
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
BRPI0417902A (pt) piperazinas úteis no tratamento da dor
BR0207644A (pt) Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 7.7 PUBLICADO NA RPI 2244 DE 07/01/2014

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.